FUNDAMENTALS · Fundamentals · JP Healthcare

CUC (9158) Fundamentals 2026 — P/E 8.3x, Revenue Analysis | SniperIQ

CUC (9158) is a JP-listed Healthcare company in Medical - Care Facilities with a market capitalization of ¥23.7B, trading at ¥808.00 on the JPX. This SniperIQ fundamentals page covers CUC's valuation (P/E 8.3x, P/B 0.7x), profitability (net margin 5.3%), revenue (¥54.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap¥23.7B
P/E (TTM)8.3x
Net Margin5.3%
Revenue (FY25)¥54.4B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is CUC's market cap?

CUC (9158) has a market capitalization of approximately ¥23.7B, trading at ¥808.00 on the JPX. Market cap moves with the live share price.

What is CUC's P/E ratio?

CUC's trailing twelve-month P/E ratio is 8.3x, with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is CUC?

CUC runs a net profit margin of 5.3%, a gross margin of 46.8%, and an operating margin of 6.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does CUC generate?

CUC reported revenue of ¥54.4B for fiscal year 2025, with net income of ¥2.9B and earnings per share (EPS) of 97.36. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does CUC pay a dividend?

CUC does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is CUC financially healthy?

CUC carries a debt-to-equity ratio of 1.58x and a current ratio of 2.03x, with a market beta of 0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is CUC a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CUC (9158) the key facts are: market cap ¥23.7B, P/E 8.3x, revenue ¥54.4B, 52-week range 686-1316. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track CUC's full fundamentals live

Get CUC's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Lepu Medical Technology (Beijing) (300003) fundamentals · Guangdong Zhongsheng Pharmaceutical (002317) fundamentals · Hualan Biological Engineering (002007) fundamentals · Incyte (INCY) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons